<DOC>
	<DOCNO>NCT01350362</DOCNO>
	<brief_summary>The main purpose study evaluate cognitive change administration tideglusib versus placebo two oral dos two treatment regime 26 week patient mild moderate Alzheimer 's disease . After 26 week core treatment period , patient may continue study blind condition optional extension period maximum 39 additional week ( total study duration 65 week ) , last patient study complete 26 week treatment .</brief_summary>
	<brief_title>Efficacy , Safety Tolerability Tideglusib Treat Mild-to-Moderate Alzheimer 's Disease Patients</brief_title>
	<detailed_description>This double-blind , placebo-controlled , randomize , parallel group study conduct multiple center European Union . Patients mild moderate Alzheimer 's disease undergo screening period , randomize one four group : tideglusib 1000 mg daily ( Q.D . ) , tideglusib 1000 mg every day ( Q.O.D . ) , tideglusib 500 mg Q.D. , match placebo , 26-week , double-blind , placebo-controlled treatment period .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Main 1 . Men woman ( nonchildbearing potential ) diagnosis probable Alzheimer 's disease . 2 . Age 50 85 year . 3 . MMSE score 14 26 . 4 . Welltolerated treatment one approve AcetylcholinesteraseInhibitors and/or Memantine stable dose Main 1 . Significant psychiatric medical disease . 2 . Any chronic liver disease indicate range value ALAT , ASAT direct bilirubin , clinically relevant hepatic steatosis clinical manifestation liver disease 3 . Chronic daily drug intake exclude concomitant medication . 4 . Enrollment another investigational drug study within 3 month baseline visit .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>tideglusib</keyword>
	<keyword>Alzheimer</keyword>
	<keyword>NP-12</keyword>
	<keyword>NP031112</keyword>
	<keyword>ARGO</keyword>
	<keyword>Noscira</keyword>
</DOC>